home / stock / cytk / cytk quote
Last: | $67.55 |
---|---|
Change Percent: | 0.18% |
Open: | $66.88 |
Close: | $67.55 |
High: | $67.8 |
Low: | $64.815 |
Volume: | 1,501,780 |
Last Trade Date Time: | 04/19/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$67.55 | $66.88 | $67.55 | $67.8 | $64.815 | 1,501,780 | 04-19-2024 |
$67 | $67.5 | $67 | $68.53 | $66.84 | 1,034,789 | 04-18-2024 |
$67.93 | $69.58 | $67.93 | $69.9 | $67.86 | 1,285,904 | 04-17-2024 |
$69 | $67.81 | $69 | $70.52 | $66.55 | 973,213 | 04-16-2024 |
$68 | $71.6 | $68 | $71.6 | $67.45 | 1,517,011 | 04-15-2024 |
$71.56 | $73.76 | $71.56 | $73.76 | $70.61 | 789,546 | 04-12-2024 |
$73.19 | $74.99 | $73.19 | $75.5 | $72.35 | 788,935 | 04-11-2024 |
$74.36 | $72.54 | $74.36 | $75 | $72.28 | 803,163 | 04-10-2024 |
$75.05 | $74.2 | $75.05 | $75.71 | $73.43 | 1,224,512 | 04-09-2024 |
$74.19 | $73.9 | $74.19 | $74.38 | $72.55 | 979,775 | 04-08-2024 |
$72.71 | $69.21 | $72.71 | $73.21 | $68.43 | 1,007,285 | 04-05-2024 |
$69.18 | $71.69 | $69.18 | $72.3299 | $68.72 | 757,951 | 04-04-2024 |
$70.92 | $70.27 | $70.92 | $71.43 | $70 | 589,413 | 04-03-2024 |
$70.97 | $71.19 | $70.97 | $72.72 | $70.345 | 1,037,252 | 04-02-2024 |
$73.02 | $69.78 | $73.02 | $73.16 | $68.9 | 1,412,087 | 04-01-2024 |
$70.11 | $71.41 | $70.11 | $71.855 | $69.96 | 1,612,736 | 03-29-2024 |
$70.11 | $71.41 | $70.11 | $71.855 | $69.96 | 1,612,736 | 03-28-2024 |
$71.41 | $71.4 | $71.41 | $73.18 | $69.88 | 2,483,051 | 03-27-2024 |
$71.15 | $69 | $71.15 | $74.6799 | $68.28 | 4,055,443 | 03-26-2024 |
$68.73 | $67.75 | $68.73 | $69.4 | $67.375 | 1,015,846 | 03-25-2024 |
News, Short Squeeze, Breakout and More Instantly...
Cytokinetics Incorporated Company Name:
CYTK Stock Symbol:
NASDAQ Market:
Primary Results from SEQUOIA-HCM to Elaborate on Positive Topline Results in Patients with Obstructive Hypertrophic Cardiomyopathy Two Additional...
Primary Results from SEQUOIA-HCM to Elaborate on Positive Topline Results in Patients with Obstructive Hypertrophic Cardiomyopathy Two Additional Analyses from SEQUOIA-HCM Assess Effect of Aficamten on Exercise Capacity and Dosing and Safety SOUTH SAN FRANCISCO, Calif., April 10...
2024-04-05 15:00:02 ET Salim Syed from Mizuho Securities issued a price target of $99.00 for CYTK on 2024-04-05 12:19:00. The adjusted price target was set to $99.00. At the time of the announcement, CYTK was trading at $72.74. The overall price target consensus is at $6...